Ozempic vs Victoza (Liraglutide): Which GLP-1 Wins in 2026?

Before Ozempic dominated the GLP-1 space, Victoza (liraglutide) was the gold standard daily GLP-1 injection for type 2 diabetes. How do they compare today — and is there any reason to choose Victoza over Ozempic in 2026? Here’s the full breakdown.

Ozempic vs Victoza: Quick Comparison

Factor	Victoza (Liraglutide)	Ozempic (Semaglutide)
Manufacturer	Novo Nordisk	Novo Nordisk
Active ingredient	Liraglutide	Semaglutide
Dosing frequency	Once daily injection	Once weekly injection
Available doses	0.6mg, 1.2mg, 1.8mg	0.25mg, 0.5mg, 1mg, 2mg
Average A1C reduction	1.0–1.5%	1.5–1.8%
Average weight loss	4–6 lbs	10–14 lbs
Cardiovascular indication	Yes (LEADER trial)	Yes (SUSTAIN-6 + SELECT trial)
FDA approval (T2D)	2010	2017
Monthly list price	~$700–$900	~$900–$1,000
Generic available	No	No

The Key Differences: Weekly vs Daily, and Weight Loss

The most practical difference is dosing frequency — once daily for Victoza vs once weekly for Ozempic. For adherence, weekly dosing wins. Missing a daily injection is far more common than missing a weekly one, and adherence directly impacts outcomes.

On weight loss, semaglutide is significantly more effective. In head-to-head data and cross-trial comparisons, semaglutide at 1mg produces roughly double the weight loss of liraglutide 1.8mg. This isn’t subtle — it’s a clinically meaningful difference that shapes prescribing decisions.

Cardiovascular Outcomes Comparison

Trial	Drug	Key Finding
LEADER	Liraglutide 1.8mg	13% reduction in MACE in T2D with high CV risk
SUSTAIN-6	Semaglutide 0.5/1mg	26% reduction in MACE in T2D with high CV risk
SELECT	Semaglutide 2.4mg	20% reduction in MACE in non-diabetic obese adults with CVD

Both drugs show cardiovascular benefit, but semaglutide’s SUSTAIN-6 effect size is larger than LEADER, and the SELECT trial adds a non-diabetic population that liraglutide has no equivalent data for.

Side Effects: Similar Profile, Different Duration

Both drugs cause GI side effects (nausea, vomiting, diarrhea) due to their shared mechanism. With daily Victoza dosing, the GI side effects are spread across more frequent injections — some patients find this means more frequent but less intense nausea. With weekly Ozempic, side effects may cluster around injection day. Individual experience varies significantly.

Is There Any Reason to Choose Victoza Over Ozempic?

In most clinical scenarios, Ozempic is the preferred agent. However, Victoza may be preferable in a few situations: patients already well-controlled on Victoza who don’t want to switch, situations where insurance covers liraglutide but not semaglutide (increasingly rare), or if Ozempic is unavailable due to shortage. Some clinicians also prefer liraglutide’s shorter half-life for patients who may need to stop quickly (e.g., surgery planned soon).

What About Saxenda vs Wegovy? (The Weight Loss Versions)

Victoza’s sister drug for obesity is Saxenda (liraglutide 3mg daily). Wegovy (semaglutide 2.4mg weekly) is Ozempic’s sister for obesity. Wegovy consistently outperforms Saxenda: 15–17% weight loss vs 5–8% for Saxenda, and with once-weekly vs once-daily dosing. This is why Saxenda’s market share has declined sharply since Wegovy’s approval.

Frequently Asked Questions

Is Victoza or Ozempic better?
Ozempic is superior for both glycemic control and weight loss in head-to-head and cross-trial comparisons. Once-weekly dosing also offers a significant adherence advantage. Most prescribers now choose semaglutide over liraglutide as first-line GLP-1 therapy.

Can you switch from Victoza to Ozempic?
Yes, this is a common transition. When switching, your prescriber will typically start semaglutide at its initiating dose (0.25mg) and titrate up, since the drugs have different potency profiles. The transition can usually happen without a washout period.

Is Victoza being discontinued?
As of 2026, Victoza is still available, but Novo Nordisk has focused commercial resources on semaglutide products (Ozempic, Wegovy, Rybelsus). Victoza’s market share has declined significantly. There have been periodic supply notices but no formal discontinuation announcement as of early 2026.

Is liraglutide cheaper than semaglutide?
Victoza list price (~$700–$900/month) is somewhat lower than Ozempic (~$900–$1,000/month), though insurance coverage and copay situations vary widely. Neither has a generic equivalent. The cost difference rarely justifies choosing the less effective drug in most clinical scenarios.